Cardiovascular Adverse Events After Anti-BCMA CAR-T (Ide-Cel and Cilta-Cel) for Relapsed/ Refractory Multiple Myeloma

被引：0
|
作者：
Palfi, Stefanie
Koelmeyer, Himara
Alsina, Melissa
Baz, Rachid
Blue, Brandon
Corallo, Salvatore
De Avila, Gabriel
Freeman, Ciara
Grajales-Cruz, Ariel
Harvey, Kristy
Liu, Hien
Nishihori, Taiga
Oliveira, Guilherme
Oswald, Laura
Puglianini, Omar Castaneda
Shain, Kenneth
Wettenstein, Zachary
Jain, Michael
Locke, Frederick
Alomar, Mohammed
Hansen, Doris
Lee, Dae Hyun
机构：
来源：
CIRCULATION | 2024年 / 150卷
关键词：
D O I：
10.1161/circ.150.suppl_1.4114505
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4114505
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
    Costa, Luciano J.
    Lin, Yi
    Cornell, R. Frank
    Martin, Thomas
    Chhabra, Saurabh
    Usmani, Saad Z.
    Jagannath, Sundar
    Callander, Natalie S.
    Berdeja, Jesus G.
    Kang, Yubin
    Vij, Ravi
    Godby, Kelly N.
    Malek, Ehsan
    Neppalli, Amarendra
    Liedtke, Michaela
    Fiala, Mark
    Tian, Hong
    Valluri, Satish
    Marino, Jennifer
    Jackson, Carolyn C.
    Banerjee, Arnob
    Kansagra, Ankit
    Schecter, Jordan M.
    Kumar, Shaji
    Hari, Parameswaran
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (05): : 326 - 335
  • [2] Trends of BCMA Re-emergence Post Ide-cel and Cilta-cel in Myeloma
    Rashid, Aliya
    Wesson, William
    Cui, Wei
    Mansour, Razan
    Mushtaq, Muhammad Umair
    Bansal, Rajat
    Balusu, Ramesh
    Lutfi, Forat
    Abhyankar, Sunil
    Shune, Leyla
    McGuirk, Joseph
    Ouchveridze, Jenny
    Abdallah, Al-Ola
    Ahmed, Nausheen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S528 - S529
  • [3] Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma
    Martin, Thomas G.
    Madduri, Deepu
    Pacaud, Lida
    Usmani, Saad Z.
    FUTURE ONCOLOGY, 2023, 19 (34) : 2297 - 2311
  • [4] Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma
    Stefanie Palfi
    Lauren C. Peres
    Himara Koelmeyer
    Melissa Alsina
    Rachid C. Baz
    Brandon J. Blue
    Salvatore Corallo
    Gabriel De Avila
    Ciara Freeman
    Rebecca Gonzalez
    Ariel Grajales-Cruz
    Kristy Harvey
    Hien D. Liu
    Taiga Nishihori
    Guilherme H. Oliveira
    Laura B. Oswald
    Omar Castaneda Puglianini
    Sruthi Selvakumar
    Alexis Behne Sharma
    Elicia Wang
    Kenneth H. Shain
    Michael Jain
    Frederick L. Locke
    Mohammed Alomar
    Doris K. Hansen
    Dae Hyun Lee
    Blood Cancer Journal, 15 (1)
  • [5] Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma
    Jagannath, Sundar
    Jackson, Carolyn C.
    Schecter, Jordan M.
    Lendvai, Nikoletta
    Sun, Huabin
    Akram, Muhammad
    Patel, Nitin
    Martin, Thomas G.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (05) : 339 - 350
  • [6] CAR plus T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma
    Harrison, Simon J.
    Touzeau, Cyrille
    Kint, Nicolas
    Li, Katherine
    Nguyen, Tamia
    Mayeur-Rousse, Caroline
    Rahman, Marzia
    Le Bris, Yannick
    Er, Jeremy
    Eugene-Lamer, Juliette
    Haynes, Nicole M.
    Li, Jessica
    Abbott, Rebecca C.
    Bodet-Milin, Caroline
    Moreau, Anne
    Letouze, Eric
    Lendvai, Nikoletta
    Schecter, Jordan M.
    Deraedt, William
    Banerjee, Arnob
    Lengil, Tamar
    Vogel, Martin
    Foulk, Brad
    Zhao, Hao
    Smirnov, Denis
    Slaughter, Ana
    Lonardi, Carolina
    Lee, Erin
    Marquez, Loreta
    Sankari, Ayah
    Plaks, Vicki
    Filho, Jose Octavio Costa
    Patel, Nitin
    Geng, Dong
    Gastinne, Thomas
    Kelly, Hannah
    Tiong, Ing Soo
    Eveillard, Marion
    Chevallier, Patrice
    Lade, Stephen
    Moreau, Philippe
    Grimmond, Sean
    Oliaro, Jane
    Tessoulin, Benoit
    Blombery, Piers
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (07): : 677 - 685
  • [7] CILTA-CEL EFFICACY AND SAFETY IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER NONCELLULAR ANTI-BCMA IMMUNOTHERAPY
    Mateos, Maria-Victoria
    Cohen, Adam
    Cohen, Yael
    Rodriguez-Otero, Paula
    Paiva, Bruno
    van de Donk, Niels
    Martin, Thomas
    Suvannasankha, Attaya
    Madduri, Deepu
    Corsale, Christina
    Schecter, Jordan
    De Braganca, Kevin
    Jackson, Carolyn
    Varsos, Helen
    Deraedt, William
    Roccia, Tito
    Mistry, Pankaj
    Xu, Xiaoying
    Li, Katherine
    Zudaire, Enrique
    Akram, Muhammad
    Pacaud, Lida
    Avivi, Irit
    San-Miguel, Jesus
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 104 - 105
  • [8] Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
    Rodriguez-Otero, Paula
    Ailawadhi, Sikander
    Arnulf, Bertrand
    Patel, Krina
    Cavo, Michele
    Nooka, Ajay K.
    Manier, Salomon
    Callander, Natalie
    Costa, Luciano J.
    Vij, Ravi
    Bahlis, Nizar J.
    Moreau, Philippe
    Solomon, Scott R.
    Delforge, Michel
    Berdeja, Jesus
    Truppel-Hartmann, Anna
    Yang, Zhihong
    Favre-Kontula, Linda
    Wu, Fan
    Piasecki, Julia
    Cook, Mark
    Giralt, Sergio
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (11): : 1002 - 1014
  • [9] Real World Outcomes with Idecabtagene Vicleucel ( Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
    Sidana, Surbhi
    Ahmed, Nausheen
    Akhtar, Othman S.
    Heim, Michael
    Brazauskas, Ruta
    Hansen, Doris K.
    Ferreri, Christopher
    Freeman, Ciara Louise L.
    Afrough, Aimaz
    Anderson, Larry D., Jr.
    Dhakal, Binod
    Dhanda, Devender
    Gowda, Lohith
    Hashmi, Hamza
    Harrison, Melanie
    Kitali, Amani
    Mirza, Sayeef
    Patel, Jinalben
    Patwardhan, Pallavi
    Usmani, Saad Z.
    Patel, Krina K.
    Ganguly, Siddhartha
    Pasquini, Marcelo
    BLOOD, 2023, 142
  • [10] Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma
    Anderson, Larry D., Jr.
    FUTURE ONCOLOGY, 2021, 18 (03) : 277 - 289
12345